RAD21 promotes oncogenesis and lethal progression of prostate cancer
Proceedings of the National Academy of Sciences · 03.09.2024 · 121 (36)
DOI: 10.1073/pnas.2405543121 ↗Kurz gefasst
Fachartikel in der Zeitschrift Proceedings of the National Academy of Sciences, online erschienen am 27.08.2024. Verfasst von Xiaofeng A Su und 17 weiteren Autor:innen. Beteiligte Einrichtung: David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139. Hauptthemen laut MEDLINE: Prostatic Neoplasms, DNA-Binding Proteins, Cell Cycle Proteins, Aneuploidy. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 68 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Paul F. Glenn Center for Biology of Aging Research, Prostate Cancer Foundation (PCF), HHMI (HHMI).
Abstract (Originalsprache)
Higher levels of aneuploidy, characterized by imbalanced chromosome numbers, are associated with lethal progression in prostate cancer. However, how aneuploidy contributes to prostate cancer aggressiveness remains poorly understood. In this study, we assessed in patients which genes on chromosome 8q, one of the most frequently gained chromosome arms in prostate tumors, were most strongly associated with long-term risk of cancer progression to metastases and death from prostate cancer (lethal disease) in 403 patients and found the strongest candidate was cohesin subunit gene, RAD21 , with an odds ratio of 3.7 (95% CI 1.8, 7.6) comparing the highest vs. lowest tertiles of mRNA expression and adjusting for overall aneuploidy burden and Gleason score, both strong prognostic factors in primary prostate cancer. Studying prostate cancer driven by the TMPRSS2-ERG oncogenic fusion, found in about half of all prostate tumors, we found that increased RAD21 alleviated toxic oncogenic stress and DNA damage caused by oncogene expression. Data from both organoids and patients indicate that increased RAD21 thereby enables aggressive tumors to sustain tumor proliferation, and more broadly suggests one path through which tumors benefit from aneuploidy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139.
- Department of Biology, Massachusetts Institute of Technology, Cambridge, MA 02139.
- Center for Prostate Disease Research, Murtha Cancer Center Research Program, Department of Surgery, Uniformed Services University of the Health Sciences, Bethesda, MD 20817.
- Henry M Jackson Foundation for the Advancement of Military Medicine Inc., Bethesda, MD 20817.
- Genitourinary Malignancies Branch, National Cancer Institute, NIH, Bethesda, MD 20817.
- Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115.
ORCID-Profile: Xiaofeng A Su, Konrad H Stopsack, Kathryn L Penney, Thomas Janas, Sofia Hu, Matthew G Vander Heiden
Förderung
- Paul F. Glenn Center for Biology of Aging Research
- Prostate Cancer Foundation (PCF)
- HHMI (HHMI)
- MIT Center for Precision Cancer Medicine, the Ludwig Center at MIT
- Bridge Project, Koch Institute for Integrative Cancer Research at MIT and the Dana-Farber/Harvard Cancer Center
- HHS | NIH | National Cancer Institute (NCI)
- PEER Award by the Zhu Center for Global Cancer Prevention
- Virginia and D.K. Ludwig Fund for Cancer Research (D.K. Ludwig Fund)
Zitieren
APA
Su, X. A., Stopsack, K. H., Schmidt, D. R., Ma, D., Li, Z., Scheet, P. A., Penney, K. L., Lotan, T. L., Abida, W., DeArment, E. G., Lu, K., Janas, T., Hu, S., Vander Heiden, M. G., Loda, M., Boselli, M., Amon, A., & Mucci, L. A. (2024). RAD21 promotes oncogenesis and lethal progression of prostate cancer. Proceedings of the National Academy of Sciences, 121(36). https://doi.org/10.1073/pnas.2405543121
Vancouver
Su XA, Stopsack KH, Schmidt DR, Ma D, Li Z, Scheet PA, et al. RAD21 promotes oncogenesis and lethal progression of prostate cancer. Proceedings of the National Academy of Sciences. 2024;121(36). doi:10.1073/pnas.2405543121
BibTeX
@article{Su2024,
author = {Su, Xiaofeng A and Stopsack, Konrad H and Schmidt, Daniel R and Ma, Duanduan and Li, Zhe and Scheet, Paul A and Penney, Kathryn L and Lotan, Tamara L and Abida, Wassim and DeArment, Elise G and Lu, Kate and Janas, Thomas and Hu, Sofia and Vander Heiden, Matthew G and Loda, Massimo and Boselli, Monica and Amon, Angelika and Mucci, Lorelei A},
title = {RAD21 promotes oncogenesis and lethal progression of prostate cancer},
journal = {Proceedings of the National Academy of Sciences},
year = {2024},
volume = {121},
number = {36},
doi = {10.1073/pnas.2405543121}
}
EUVIMED